生物分子缩物在肌缩性侧面硬化症中的影响
Hana Fakim1, Christine Vande Velde1
1Department of Neurosciences, Université de Montréal, and CHUM Research Center, Montréal, QC, Canada.
Seminars in cell & developmental biology
|June 2, 2023
概括
本综述探讨了TDP-43和FUS蛋白在正常细胞结构中的功能,而不仅仅是压力颗粒,以及突变如何影响肌缩侧面硬化症 (ALS) 中的这些过程. 了解这些生理凝聚物是ALS研究的关键.
科学领域:
- 神经生物学 神经生物学 神经生物学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 肌缩侧面硬化症 (ALS) 与TDP-43和FUS的突变有关,这些蛋白质存在于压力颗粒中.
- 压力颗粒与ALS的发病有关,但它们的蛋白质成分也存在于其他生理生物分子凝聚物中.
- 这些其他凝结物在ALS中的作用仍未得到充分探索.
研究的目的:
- 检查TDP-43和FUS在生理学,压力独立的生物分子凝聚物的功能.
- 调查ALS相关突变如何影响TDP-43和FUS相分离以及这些凝结物的功能.
- 突出失调的生理凝结物对ALS病理学的潜在贡献.
主要方法:
- 文献综述侧重于TDP-43和FUS在核和神经缩物中的作用.
- 对ALS相关突变及其对蛋白质相分离的影响现有研究的分析.
- 讨论ALS对RNA代谢的影响.
主要成果:
- TDP-43和FUS是各种生理凝聚物的组成部分,包括核细胞,Cajal体,粒和神经元RNA颗粒.
- 与ALS相关的突变可能会损害这些压力独立冷凝物中的TDP-43和FUS的相分离和功能.
- 这些凝聚物的失调可能解释了ALS对RNA代谢的广泛影响.
结论:
- 仅仅关注压力颗粒,就忽略了TDP-43和FUS在ALS相关的生理凝结物中的关键作用.
- 了解核和神经质凝聚物中TDP-43和FUS的行为,为ALS的发病过程提供了新的见解.
- 这些凝结物的异常相位分离为ALS提供了潜在的治疗点.
相关概念视频
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Cross-bridge Cycle
117.8K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
117.8K
Alzheimer's Disease: Overview
539
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
539


